T&R Biofab (246710) Fundamentals 2026 — Revenue Analysis | SniperIQ
T&R Biofab (246710) is a KR-listed Healthcare company in Medical - Specialties with a market capitalization of ₩43.7B, trading at ₩2030.00 on the KOE. This SniperIQ fundamentals page covers T&R Biofab's valuation, profitability (net margin -105.0%), revenue (₩27.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is T&R Biofab's market cap?
T&R Biofab (246710) has a market capitalization of approximately ₩43.7B, trading at ₩2030.00 on the KOE. Market cap moves with the live share price.
What is T&R Biofab's P/E ratio?
T&R Biofab's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is T&R Biofab?
T&R Biofab runs a net profit margin of -105.0%, a gross margin of 21.9%, and an operating margin of -22.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does T&R Biofab generate?
T&R Biofab reported revenue of ₩27.0B for fiscal year 2025, with net income of -₩34.8B and earnings per share (EPS) of -759.93. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does T&R Biofab pay a dividend?
T&R Biofab does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is T&R Biofab financially healthy?
T&R Biofab carries a debt-to-equity ratio of 1.41x and a current ratio of 1.03x, with a market beta of 0.46. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is T&R Biofab a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For T&R Biofab (246710) the key facts are: market cap ₩43.7B, revenue ₩27.0B, 52-week range 1127-4925. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track T&R Biofab's full fundamentals live
Get T&R Biofab's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.